Evidence map›Paper›PMID 41382999›Full record

ReviewZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

Deep space environment empowering drug design and development.

Yanpeng Fang, Bin Feng, Weizheng Li, Liyong Zhu, Fei Chen, Wenbin Zeng

Abstract readReview
In one paragraph

Review in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanpeng FangDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013. 247201014@csu.edu.cn.
Bin FengDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013.
Weizheng LiDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Liyong ZhuDepartment of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Fei ChenDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013.
Wenbin ZengDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013. wbzeng@csu.edu.cn.

Funding

the National Natural Science Foundation of China 82272067
6 · The paper itself

Abstract

The unique characteristics of the deep space environment, microgravity, cosmic radiation, and extreme temperature fluctuations, are emerging as major driving forces for pharmaceutical innovation. These factors provide new avenues for optimizing drug formulations, improving crystal structure quality, and accelerating the discovery of therapeutic targets. Advances in deep space research not only help overcome critical bottlenecks in terrestrial drug development but also promote progress in structure-based drug design and deepen understanding of cellular stress-response mechanisms. Current progress in space-based pharmaceutical research primarily includes the study of disease mechanisms under microgravity, protein crystallization in microgravity, and drug development utilizing deep space radiation and resources. However, the operational complexity, high costs, and limited data reproducibility of space experiments remain key challenges hindering widespread application. Looking ahead, with the integration of automation, artificial intelligence analysis, and on-orbit manufacturing, deep space drug development is expected to achieve greater scalability and precision, opening a new frontier in biopharmaceutical science.

Indexed as

Drug DesignDrug DevelopmentExtraterrestrial EnvironmentSpace FlightArtificial IntelligenceHumansWeightlessnessdeep space environmentdrug developmentmicrogravityprotein crystallizationradiation

Identifiers

PMID41382999
PMCPMC12723246

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.